(Guidance document published by the Federation of Asian Pharmaceutical Associations on March 16, 2020). This guidance document is part of FAPA’s response to an outbreak of respiratory disease called “coronavirus disease 2019” ( COVID-19), which is caused by a novel (new) coronavirus now officially called “SARS-CoV-2”. COVID-19 is now affecting more than 100 countries and was publicly characterized as a pandemic by the World Health Organization (WHO) on March 11, 2020.

Click HERE to read more